Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial.
Bora LeeWonjun JiJae Cheol LeeSi Yeol SongYoung Seob ShinYoung Hyun ChoJi Eun ParkHyung Jun ParkChang-Min ChoiPublished in: Thoracic cancer (2023)
Lazertinib, in combination with local therapy for the brain, if necessary, is expected to improve the clinical benefit in advanced EGFR mutation-positive NSCLC with brain metastases, as a first-line treatment.